LEADER 00929nam 2200337 450 001 990005821290203316 005 20130326131026.0 010 $a88-14-18025-3 035 $a000582129 035 $aUSA01000582129 035 $a(ALEPH)000582129USA01 035 $a000582129 100 $a20130326d2012----km-y0itay50------ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> diversità nelle leggi$fVittorio Italia 210 $aMilano$cGiuffré$d2012 215 $aXIV, 107 p.$d254 cm 606 0 $aLeggi$2BNCF 676 $a342.4505 700 1$aITALIA,$bVittorio$0334403 801 0$aIT$bsalbc$gISBD 912 $a990005821290203316 951 $aXXIV.2.C. 179$b76338 G.$cXXIV.2.C.$d00314026 959 $aBK 969 $aGIU 979 $aCHIARA$b90$c20130326$lUSA01$h1310 979 $aCHIARA$b90$c20130326$lUSA01$h1310 996 $aDiversità nelle leggi$91089070 997 $aUNISA LEADER 02327nam 2200613Ia 450 001 9910451392003321 005 20200520144314.0 010 $a1-280-81164-1 010 $a9786610811649 010 $a0-85199-946-8 035 $a(CKB)1000000000344556 035 $a(EBL)292075 035 $a(OCoLC)476051543 035 $a(SSID)ssj0000160710 035 $a(PQKBManifestationID)11154748 035 $a(PQKBTitleCode)TC0000160710 035 $a(PQKBWorkID)10190417 035 $a(PQKB)11730828 035 $a(MiAaPQ)EBC292075 035 $a(Au-PeEL)EBL292075 035 $a(CaPaEBR)ebr10170090 035 $a(CaONFJC)MIL81164 035 $a(EXLCZ)991000000000344556 100 $a20000414d2000 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aGanoderma diseases of perennial crops$b[electronic resource] /$fedited by J. Flood, P.D. Bridge, M. Holderness 210 $aWallingford, UK ;$aNew York $cCABI Pub.$dc2000 215 $a1 online resource (287 p.) 300 $aDescription based upon print version of record. 311 $a0-85199-388-5 320 $aIncludes bibliographical references and index. 327 $aContributors; Preface; I Ganoderma, Organism and Systematics; II Ganoderma, Diseases of Perennial Crops; III Disease Control and Management Strategies; IV Molecular Variability in Ganoderma; V Development of Diagnostic Tests for Ganoderma; Index 330 $aGanoderma is a fungal pathogen that causes diseases on a variety of perennial crops including oil, palm, tea, rubber and coconut. Chapters in the book are based on presentations given at regional research workshops, held in Egham, UK in August 1998, and Serdang, Malaysia in October 1998. 606 $aGanoderma 606 $aGanoderma diseases of plants 608 $aElectronic books. 615 0$aGanoderma. 615 0$aGanoderma diseases of plants. 676 $a632.497 676 $a632/.4 701 $aFlood$b J$g(Julie)$0969454 701 $aBridge$b P. D$0874112 701 $aHolderness$b M$g(Mark)$0969455 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451392003321 996 $aGanoderma diseases of perennial crops$92203028 997 $aUNINA LEADER 11160nam 2200577 450 001 9910495252103321 005 20231110225204.0 010 $a3-030-54564-4 035 $a(CKB)4100000012009052 035 $a(MiAaPQ)EBC6712967 035 $a(Au-PeEL)EBL6712967 035 $a(OCoLC)1265461604 035 $a(PPN)25735185X 035 $a(EXLCZ)994100000012009052 100 $a20220605d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aModern approaches to augmentation of brain function /$fIoan Opris, Mikhail A. Lebedev, Manuel F. Casanova 210 1$aCham, Switzerland :$cSpringer International Publishing,$d[2021] 210 4$d©2021 215 $a1 online resource (747 pages) 225 1 $aContemporary Clinical Neuroscience 311 $a3-030-54563-6 327 $aIntro -- Foreword -- Preface -- Human Intellectual Capacity and Its Growth -- Modern Approaches to Brain Augmentation -- Part I: Stimulating the Brain -- Part II: Brain-Computer Interfaces -- Part III: Augmenting Cognitive Function -- Part IV: Futuristic Approaches to Augmentation -- Part V: Augmenting Behavior -- Part VI: Augmenting Cognition and Emotion -- Part VII: Pharmacological Augmentation -- Contents -- Part I: Stimulating the Brain -- Using Electrical Stimulation to Explore and Augment the Functions of Parietal-Frontal Cortical Networks in Primates -- 1 Introduction -- 2 Electrical Stimulation: A Selective and Brief History -- 3 The Action-Specific Parietal-Frontal Network of Primates -- 4 The Functions of the Action-Specific Domains in Primates -- 5 The Basal Ganglia: Further Steps in the Action Selection Hierarchy -- 6 Using Electrical Stimulation to Augment Action Selection -- References -- Spinal Cord Injury and Epidural Spinal Cord Stimulation -- 1 Introduction: Revisiting Low Expectations for Neurological Recovery After "Complete" SCI -- 2 Reinterpreting the Lack of Apparent Success of Drugs, Cell Transplants, and Biologics -- 2.1 Early Neuromodulation: Electrical Stimulation of Muscle to Restore Function -- 2.2 Spinal Cord Stimulation -- 3 Concepts that Supported the Testing of Epidural Stimulation for Recovery in SCI -- 3.1 Discomplete Spinal Cord Injury -- 3.2 Early ES Observations in SCI Subjects to Treat Spasticity -- 3.3 Neuroplasticity -- 3.4 The Emerging Understanding of Intraspinal Connectivity -- 3.5 Intraspinal Circuits for Reciprocating Activity -- 3.6 Spontaneous Locomotor Activity Observed After Chronic Human SCI -- 4 Epidural Electrical Stimulation, Spinal Cord Injury, and Locomotion -- 4.1 Locomotor Activity Resulting from Electrical Epidural Stimulation -- 4.2 Locomotor Training and Sensory Input. 327 $a4.3 Reported Effects of ES on Autonomic Functions -- 5 Transcutaneous Stimulation -- 6 Potential ES Synergies -- 7 The Essential Role of Spinal Cord Repair Research -- 8 Conclusions -- References -- Neurostimulator for Hippocampal Memory Prosthesis -- 1 Introduction -- 2 Materials and Design -- 2.1 Stimulation Pattern Generator Circuit -- 2.2 Stimulus Artifact Suppression Technique -- 2.3 Electrochemical Properties -- 2.4 System Architecture -- 2.5 Power Calculation -- 2.6 System Cost -- 3 Experimental Methods -- 3.1 Design Characterization -- 3.2 In Vivo Evaluation -- 4 Notes -- References -- Modern Approaches to Augmenting the Brain Functions -- 1 Introduction -- 2 Augmentation Approaches -- 2.1 Neuromodulation -- 2.2 Brain-Computer Interfaces -- 2.3 Futuristic Transfer of Brain Ability -- 3 Augmenting Brain Functions -- 3.1 Sensory Augmentation -- 3.2 Motor Augmentation -- 3.3 Augmentation of Cognition -- 3.4 Augmentation of Emotions -- 4 Clinical Applications -- 4.1 Autism -- 4.2 Depression -- 4.3 Alzheimer's Disease -- 4.4 Post-traumatic Stress Disorder (PTSD) -- 4.5 Drug Addiction -- 4.6 Parkinson's Disease -- 4.7 Seizures -- 5 Technology for Brain Augmentation -- 5.1 Neural Engineering -- 5.2 Optogenetic Augmentation of Brain Function -- 5.3 Neural Nanotechnology -- 5.4 Neural Spintronics -- 5.5 Tools Advances Based on the Interaction with the Brain -- 5.6 Devices for Brain Augmentation -- 6 Ethical Issues -- 7 Conclusion -- References -- Part II: Brain-Computer Interfaces -- Brain Machine Interfaces Within a Critical Perspective -- 1 Introduction -- 2 Roles in Cognition and Behavior -- 3 Sensory-Motor Functions -- 4 Ontological Criticalities -- 5 Interfacing With the Neural Code -- 6 Cascades of Complex Factors -- 7 Neuroprothesis and Historical Attempts -- 8 Conclusions -- References. 327 $aAn Implantable Wireless Device for ECoG and Cortical Stimulation -- 1 Introduction -- 2 Preliminary Experience in Primates -- 3 Clinical Applications of Wireless ECoG: Preliminary Experience in Epilepsy Surgery -- 4 Conclusions -- References -- BCI Performance Improvement by Special Low Jitter Quasi-Steady-State VEP Paradigm -- 1 Introduction -- 2 Materials and Methods -- 2.1 Continuous Loop Averaging Deconvolution (CLAD) -- 2.2 Stimulator and Stimuli Design -- 2.3 EEG Recording and Signal Processing -- 2.4 Classification -- 3 Results -- 3.1 ANOVA Results -- 3.2 SSVEP Vs. QSS-VEP Comparison -- 4 Discussions -- 5 Conclusion -- References -- Communication with Brain-Computer Interfaces in Medical Decision-Making -- 1 Introduction -- 2 Decoding and Communicating -- 3 Extracortical and Intracortical BCIs for Communication -- 4 Ethical Issues in BCI-Based Communication -- 5 A Case Study -- 6 Conclusion -- References -- Part III: Augmenting Cognitive Function -- Neuroprotection and Neurocognitive Augmentation by Photobiomodulation -- 1 Introduction -- 2 Part 1: Animal Studies-Prevention of Neurodegeneration and Behavioral Deficits by Photobiomodulation -- 2.1 Objectives of Animal Studies of Neuroprotection by Photobiomodulation -- 2.2 Significance of Animal Studies of Neuroprotection by Photobiomodulation -- 2.3 Cytochrome Oxidase as a Molecular Target of Photobiomodulation -- 2.4 In Vitro Neuroprotective Effects of Cytochrome Oxidase Stimulation by Photobiomodulation -- 2.5 In Vivo Light Delivery and Dosing Considerations -- 2.6 Mitochondrial Dysfunction in Neurodegenerative Disorders and Therapeutic Role of Photobiomodulation -- 2.7 Photobiomodulation Prevents Impairment of Visual Function in a Rat Model of Optic Neuropathy Induced by Mitochondrial Dysfunction -- 2.8 Photobiomodulation Prevents Structural Retinal Damage in the Model of Optic Neuropathy. 327 $a2.9 Protective Effects of Photobiomodulation Are Not Related to Photodegradation of Rotenone -- 2.10 Preservation of Visual Function and Retinal Structure Are Not Mediated by Isoflurane Exposure -- 2.11 Photobiomodulation Prevents Decreases in Cell Respiration in Brain Homogenates In Vitro -- 2.12 Photobiomodulation Increases Brain Antioxidant Capacity in a Dose-Response Manner In Vivo -- 2.13 A Single Dose of Photobiomodulation Enhances Brain Cytochrome Oxidase Activity in a Hormetic Fashion In Vivo -- 2.14 Fractionated Photobiomodulation Increases Brain Cytochrome Oxidase Activity in a Dose-Response Manner In Vivo -- 3 Part 2: Human Studies-Augmentation of Neurocognitive Functions by Photobiomodulation -- 3.1 Introduction and Objectives of the Human Studies -- 3.2 Significance of Human Cognitive Enhancement by Photobiomodulation -- 3.3 Cytochrome Oxidase as Molecular Target for Human Cognitive Enhancement -- 3.4 Need to Investigate How TILS Affects Human Neurocognitive Function -- 3.5 Overview of Our Approach for Human Cognitive Enhancement by Photobiomodulation -- 3.6 Cognitive-Enhancing Effects of TILS of the Human Prefrontal Cortex -- 3.6.1 Cognitive Benefits of TILS in Older Participants -- 3.7 Neurophysiological Effects of TILS of the Human Prefrontal Cortex -- 4 Conclusions -- References -- Avoiding Partial Sleep: The Way for Augmentation of Brain Function -- 1 Sleep and "Human Factor" -- 2 Peculiarities of Sleep Deprivation Effects -- 3 Modern Theories of Sleep -- 4 Phenomenon of Partial (Local) Sleep -- 5 Partial Sleep and Cognitive Impairments After Sleep Deprivation -- 6 Whether Cortical EEG Reflects Peculiarity of Brain Activity in Wakefulness and Sleep, or Just Pattern of the Cortical Afferent Flow? -- 7 Which Signals Could Provide Periodic and Synchronous Afferentation During Sleep?. 327 $a8 Experimental Validation of the Visceral Hypothesis of Sleep -- 9 The Visceral Sleep Theory and Observations of "Slow-Wave" Activity in the Cortical Slabs and Slices -- 10 The Pathways for the Visceral Afferentation to the Cerebral Cortex During Sleep -- 11 K-Complexes and Visceral Afferentation, Use Dependency, and Sleep Homeostasis -- 12 Mechanism of Sleep Initiation and Features of Local Sleep -- 13 Conclusion -- References -- Augmentation of Brain Functions by Nanotechnology -- 1 Nanotechnologies in Neuroscience -- 2 Nanoparticles -- 3 Nanoparticle Formulations in the Diagnosis and Therapy of Alzheimer's Disease -- 4 Multimodal Nanoparticles Labeling of Neurons -- 4.1 Quantum Dots -- 5 Nanoparticle-Based Therapeutics for Brain Injury -- 6 Nanotherapeutic Approaches -- 6.1 Exosomes as a Communication Tool -- 7 Overcoming BBB to Treat Neurodegenerative Diseases -- 8 Neuromodulation of the Brain -- 9 Noninvasive Neuromodulation by Magneto-Electric Nanoparticles -- 10 Nanoelectrical and Chemical Stimulation -- 11 Neuroengineering -- 12 Sensors -- 12.1 Magnetic Tunneling Junctions Sensor -- 12.2 Optical Probes for Neurobiological Sensing and Imaging -- 13 Biosensors -- 14 Neuronal Recording -- 15 Multisite Attenuated Intracellular Recordings by Extracellular Multielectrode Arrays -- 16 Interface Microelectrodes for Ultrasensitive Monitoring of Alzheimer's Disease -- 17 Resistive Memory Devices -- 18 Brain-Machine Interfaces -- 19 Conclusion -- 20 Future Directions -- References -- The Impact of Aging and Age-Related Comorbidities on Stroke Outcome in Animal Models and Humans -- 1 Introduction -- 2 The Risk of Cerebral Ischemia Increases with Age -- 3 Cerebral Ischemia and Comorbidities -- 4 Stroke Models Using Aged Animals Are Clinically More Relevant -- 5 Age-Dependent Recovery from Cerebral Ischemia. 327 $a6 Spontaneous Stroke Recovery in Aged Patients and Animals. 410 0$aContemporary Clinical Neuroscience 606 $aNeurosciences$xResearch 606 $aNeurociències$2thub 606 $aInvestigació mèdica$2thub 608 $aLlibres electrònics$2thub 615 0$aNeurosciences$xResearch. 615 7$aNeurociències 615 7$aInvestigació mèdica 676 $a616.890072 700 $aOpris?$b Ioan$0964613 702 $aLebedev$b Mikhail$g(Mikhail A.), 702 $aCasanova$b Manuel F. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910495252103321 996 $aModern Approaches to Augmentation of Brain Function$92188549 997 $aUNINA